BACKGROUND: This study was designed to assess the diagnostic value of the oral calcium tolerance test with measurement of intact parathyroid hormone by the immunoradiometric assay (IRMA PTH) in the diagnosis of primary hyperparathyroidism in patients with symptoms who have minimal, intermittent, or no elevation of the levels of total calcium and/or intact PTH. METHODS: After baseline levels of IRMA PTH and total calcium were measured, an oral calcium load of 1000 mg elemental calcium was administered to 10 patients with hyperparathyroidism and 18 normal control subjects. Total calcium and IRMA PTH levels were measured at 30, 60, and 120 minutes after the oral calcium load was administered. RESULTS: The mean suppression of the baseline level of IRMA PTH in the patients with hyperparathyroidism was 83.7% +/- 6.5% (mean +/- 1 SEM), but the levels of the normal control subjects fell significantly (p < 0.05) lower to 58.8% +/- 3.7% (mean +/- 1 SEM). CONCLUSIONS: This study suggests that the oral calcium tolerance test may be a valuable adjunct in confirming the diagnosis of primary hyperparathyroidism in patients with symptoms who have minimal, intermittent, or no elevation of the levels of total calcium and/or IRMA PTH:
BACKGROUND: This study was designed to assess the diagnostic value of the oral calcium tolerance test with measurement of intact parathyroid hormone by the immunoradiometric assay (IRMA PTH) in the diagnosis of primary hyperparathyroidism in patients with symptoms who have minimal, intermittent, or no elevation of the levels of total calcium and/or intact PTH. METHODS: After baseline levels of IRMA PTH and total calcium were measured, an oral calcium load of 1000 mg elemental calcium was administered to 10 patients with hyperparathyroidism and 18 normal control subjects. Total calcium and IRMA PTH levels were measured at 30, 60, and 120 minutes after the oral calcium load was administered. RESULTS: The mean suppression of the baseline level of IRMA PTH in the patients with hyperparathyroidism was 83.7% +/- 6.5% (mean +/- 1 SEM), but the levels of the normal control subjects fell significantly (p < 0.05) lower to 58.8% +/- 3.7% (mean +/- 1 SEM). CONCLUSIONS: This study suggests that the oral calcium tolerance test may be a valuable adjunct in confirming the diagnosis of primary hyperparathyroidism in patients with symptoms who have minimal, intermittent, or no elevation of the levels of total calcium and/or IRMA PTH:
Authors: Jens Bollerslev; Lars Rejnmark; Alexandra Zahn; Ansgar Heck; N M Appelman-Dijkstra; Luis Cardoso; Fadil M Hannan; Filomena Cetani; Tanja Sikjær; Anna Maria Formenti; Sigridur Björnsdottir; Camilla Schalin-Jantti; Zhanna Belaya; Fraser Wilson Gibb; Bruno Lapauw; Karin Amrein; Corinna Wicke; Corinna Grasemann; Michael Krebs; Eeva M Ryhänen; Ozer Makay; Salvatore Minisola; Sebastien Gaujoux; Jean-Philippe Bertocchio; Zaki K Hassan-Smith; Agnès Linglart; Elizabeth M Winter; Martina Kollmann; Hans-Georg Zmierczak; Elena Tsourdi; Stefan Pilz; Heide Siggelkow; Neil J Gittoes; Claudio Marcocci; Peter Kamenicky Journal: Eur J Endocrinol Date: 2022-01-13 Impact factor: 6.664